Suchergebnisse

Since previous reviews of epidemiologic studies of premature mortality among people with epilepsy were completed several years ago, a large body of new evidence about this subject has been published. We aim to update prior reviews of mortality in epilepsy and to reevaluate and quantify the risks, potential risk factors, and causes of these deaths. We systematically searched the Medline and Embase databases to identify published reports describing mortality risks in cohorts and populations of people with epilepsy. We reviewed relevant reports and applied criteria to identify those studies likely to accurately quantify these risks in representative populations. From these we extracted and summarized the reported data. All population-based studies reported an increased risk of premature mortality among people with epilepsy compared to general populations. Standard mortality ratios are especially high among people with epilepsy aged <50 years, among those whose epilepsy is categorized as structural/metabolic, those whose seizures do not fully remit under treatment, and those with convulsive seizures. Among deaths directly attributable to epilepsy or seizures, important immediate causes include sudden unexpected death in epilepsy (SUDEP), status epilepticus, unintentional injuries, and suicide. Epilepsy-associated premature mortality imposes a significant public health burden, and many of the specific causes of death are potentially preventable. These require increased attention from healthcare providers, researchers, and public health professionals. ; UpsherSmith ; Cyberonics ; Department of Rehabilitation ; Mount Sinai Medical Center ; New York University Langone Comprehensive Epilepsy Center ; National Institutes of Health ; Centers for Disease Control and Prevention ; Epilepsy Study Consortium ; Epilepsia ; Wellcome Trust, United Kingdom ; Department of Health's NIHR Biomedical Research Centres ; Marvin Weil Epilepsy Research Fund ; GlaxoSmithKline (GSK) ; Eisai ; UCB ; European Union ; Dutch Epilepsy Funds ; World Health Organization (WHO) ; United Kingdom Epilepsy Society ; GlaxoSmithKline ; Novartis ; Bial ; Citizens United for Research in Epilepsy (CURE) ; Stockholm County Council ; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA ; Univ Bari Aldo Moro, Pia Fdn Cardinale G Panico, Dept Clin Res Neurol, Lecce, Italy ; Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy ; Mario Negri Inst Pharmacol Res, Milan, Italy ; Columbia Univ, Sergievsky Ctr, New York, NY USA ; Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA ; UCL, Inst Child Hlth, Dept Neurosci, London, England ; Muhimbili Univ Hlth & Allied Sci, Dept Paediat, Dar Es Salaam, Tanzania ; Univ Oxford, Dept Psychiat, Oxford, England ; Univ Fed Sao Paulo, Dept Neurol & Neurosurg, Sao Paulo, Brazil ; UCL Inst Neurol, NIHR Univ Coll London Hosp, Biomed Res Ctr, London, England ; Epilepsy Inst Netherlands Fdn SEIN, Heemstede, England ; Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden ; Department of Neurology and Neurosurgery, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil ; Web of Science